Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cytek Biosciences (CTKB) EBITDA (2020 - 2026)

Cytek Biosciences filings provide 6 years of EBITDA readings, the most recent being -$42.7 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 546.32% to -$42.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$64.3 million, a 1259.99% decrease, with the full-year FY2025 number at -$64.3 million, down 1259.7% from a year prior.
  • EBITDA hit -$42.7 million in Q4 2025 for Cytek Biosciences, down from -$4.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $9.6 million in Q4 2024 to a low of -$42.7 million in Q4 2025.
  • Median EBITDA over the past 5 years was -$1.6 million (2022), compared with a mean of -$3.6 million.
  • Biggest five-year swings in EBITDA: skyrocketed 169.63% in 2022 and later tumbled 823.04% in 2023.
  • Cytek Biosciences' EBITDA stood at $1.3 million in 2021, then soared by 169.63% to $3.6 million in 2022, then soared by 63.53% to $5.8 million in 2023, then soared by 64.58% to $9.6 million in 2024, then crashed by 546.32% to -$42.7 million in 2025.
  • The last three reported values for EBITDA were -$42.7 million (Q4 2025), -$4.6 million (Q3 2025), and -$5.0 million (Q2 2025) per Business Quant data.